Interim Report

January 1 – June 30, 2017

The second quarter in figures

  • Net sales amounted to TSEK 2,046 (1,855).
  • The loss after tax amounted to TSEK 11,746 (14,468).
  • The loss per share amounted to SEK 1.42 (1.75).
  • The cash flow from current operations was negative in the amount of TSEK 11,044 (13,112).
  • The gross margin in the period was 34.2% (30.1%).

The first 6 months in figures

  • Net sales amounted to TSEK 3,801 (2,921).
  • The loss after tax amounted to TSEK 23,358 (26,068).
  • The loss per share amounted to SEK 2.82 (3.15).
  • The cash flow from current operations was negative in the amount of TSEK 23,025 (24,359).
  • The gross margin in the period was 30.6% (28.7%).

Important events during the quarter

  • In June the Company announced that the US Food and Drug Administration (FDA) had approved SciBase’s Pre-market Approval (PMA) for its product Nevisense.
  • The Australian study previously presented at the World Congress of Cancers of the Skin showing that Nevisense can detect malignant melanoma three months earlier in follow-up cases and reduce the need for follow-up by nearly half, was published in the British Journal of Dermatology (BJD). 
  • At the 2017 AGM held on May 16th, three new members of the Board were elected strengthening the commercial experience of the Board in Germany and the US.
  • SciBase was granted a US patent for the electrode design. 
  • David Melin was appointed as new Head of Product Development.
  • SciBase relocated from central Stockholm to Sundbyberg (a suburb to Stockholm). 

Important events after the end of the period

  • At the British Association of Dermatologist’s annual meeting in July a new study from Southampton University Hospital was presented showing Nevisense’s potential to help clinicians detect melanomas that otherwise could have been missed.
July 1 2016 -
Apr 1 - Jun 30 Jan 1 - Jun 30 June 30 2017 Jan 1 - Dec 31
THE GROUP 2017 2016 2017 2016 Rolling-12 2016
Net sales, SEK ths 2 046 1 855 3 801 2 921 7 316 6 436
Gross margin, % 34,2% 30,1% 30,6% 28,7% 34,8% 34,5%
Equity/Asset ratio, % 87,2% 92,7% 87,2% 92,7% 87,2% 90,8%
Net indebtness, multiple 0,15 0,08 0,15 0,08 0,15 0,10
Cash equivalents, SEK ths 60 974 108 786 60 974 108 786 60 974 84 955
Cashflow from operating activities, SEK ths -11 044 -13 112 -23 025 -24 359 -46 516 -47 850
Earnings per share (before and after dilution), SEK -1,42 -1,75 -2,82 -3,15 -6,08 -6,41
Shareholder's equity per share, SEK 8,38 14,45 8,38 14,45 8,38 11,19
Average number of shares, 000' 8 285 8 285 8 285 8 285 8 285 8 285
Number of shares at closing of period, 000' 8 285 8 285 8 285 8 285 8 285 8 285
Share price at end of period, SEK 23,40 17,20 23,40 17,20 23,40 19,00
Average number of employees 21 19 22 19 22 21


This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August18, 2017.

Simon Grant, CEO, tel:  +46 72 887 43 99 , simon.grant@SciBase.com

Michael Colérus, CFO, tel: +46 70 341 34 72, michael.colérus@SciBase.com

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com 

Tags:

About Us

SciBase is a Swedish medical technology company founded in 1998 that has developed Nevisense, a point-of-care device for the accurate detection of malignant melanoma. Nevisense has emerged from more than 20 years of research at Karolinska Institute in Stockholm and at SciBase. The device is designed to be provide additional information when evaluating lesions with a suspicion of melanoma. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. The CE-marked system consists of an electrode on a hand-held probe connected to a small portable device performing the analysis and displaying the result. A video describing the Nevisense method is available on: www.scibase.se/en/the-nevisenseproduct and further information is also available on www.scibase.com.

Subscribe

Documents & Links